The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Follicular lymphoma: 2020 update on diagnosis and management
Open accessAbstract
Disease overview: Follicular lymphoma (FL) is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, and splenomegaly. Extranodal involvement is less common. Cytopenias are relatively common but constitutional symptoms of fever, night sweats, and weight loss are uncommon in the absence of transformation to diffuse large B cell lymphoma. Diagnosis: The diagnosis is based on histology from a biopsy of a lymph node or other affected tissue. Incisional biopsy is preferred over needle biopsies in order to give adequate tissue to assign grade and assess for transformation. Immunohistochemical staining is positive in virtually all cases for cell surface CD19, CD20, CD10 and monoclonal immunoglobulin, as well as cytoplasmic expression of bcl‐2 protein. The overwhelming majority of cases have the characteristic t(14;18) translocation involving the IgH/bcl‐2 genes. Risk stratification: The Follicular Lymphoma International Prognostic Index (FLIPI) uses five independent predictors of inferior survival: age > 60 years, hemoglobin <12 g/dL, serum LDH > normal, Ann Arbor stage III/IV, number of involved nodal areas >4. The presence of 0‐1, 2, and ≥ 3 adverse factors defines low, intermediate, and high‐risk disease. There are other clinical prognostic models but the FLIPI remains the most common. Other factors such as time to relapse of less than 2 years from chemoimmunotherapy and specific gene mutations may also be useful for prognosis. Regardless of the prognostic model used, modern therapies have demonstrably improved prognosis. Risk‐adapted therapy: Observation continues to be appropriate for asymptomatic patients with low bulk disease and no cytopenias. There is no overall survival advantage for early treatment with either chemotherapy or single agent rituximab. For patients needing therapy, most patients are treated with chemoimmunotherapy, which has improved response rates, duration of response and overall survival (OS). Randomized studies have shown additional benefit for maintenance rituximab. Lenalidomide was non‐inferior to chemoimmunotherapy in a randomized front‐line study and, when combined with rituximab, was superior to rituximab alone in relapsed FL. Kinase inhibitors, other immunotherapies, and stem cell transplantation (SCT) are also considered for recurrent disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D., Chan, W. C., Fisher, R. I., Braziel, R. M., Rimsza, L. M., Grogan, T. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041869 · Cited by 1,418
Follicular lymphoma international prognostic index
Solal-Celigny, P. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0036-3 · Cited by 1,339
Hiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,320
Salles, G., Seymour, J. F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,079
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Marcus, R. (2005) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 967
Casulo, C., Byrtek, M., Dawson, K. L., Zhou, X., Farber, C. M., Flowers, C. R., Hainsworth, J. D., Maurer, M. J., Cerhan, J. R., Link, B. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7534 · Cited by 850
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E., Sangha, R., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 800
Federico, M., Bellei, M., Marcheselli, L., Luminari, S., Lopez-Guillermo, A., Vitolo, U., Pro, B., Pileri, S., Pulsoni, A., Soubeyran, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3991 · Cited by 751
131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041511 · Cited by 716
Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haïoun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah, I., & Solal-Céligny, P. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1110 · Cited by 647
Flinn, I. W., van der Jagt, R., Kahl, B. S., Wood, P., Hawkins, T. E., MacDonald, D., Hertzberg, M., Kwan, Y.-L., Simpson, D., Craig, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-531327 · Cited by 643
Follicular Lymphoma International Prognostic Index
Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2003-12-4434 · Cited by 626
Pastore, A., Jurinovic, V., Kridel, R., Hoster, E., Staiger, A. M., Szczepanowski, M., Pott, C., Kopp, N., Murakami, M., Horn, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00169-2 · Cited by 618
Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J. V., Dmoszynska, A., Raposo, J. C., Offner, F. C., Gomez-Codina, J., Belch, A., Cunningham, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5376 · Cited by 594
van Oers, M. H. J., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Gascoyne, R. D., Jack, A., van't Veer, M., Vranovsky, A., Holte, H., et al. (2006) · Blood · doi:10.1182/blood-2006-05-021113 · Cited by 592
Forstpointner, R. (2004) · Blood · doi:10.1182/blood-2004-04-1323 · Cited by 580
Carreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A., Roncador, G., Montserrat, E., Campo, E., & Banham, A. H. (2006) · Blood · doi:10.1182/blood-2006-04-018218 · Cited by 503
Farinha, P., Masoudi, H., Skinnider, B. F., Shumansky, K., Spinelli, J. J., Gill, K., Klasa, R., Voss, N., Connors, J. M., & Gascoyne, R. D. (2005) · Blood · doi:10.1182/blood-2005-04-1565 · Cited by 461
Rummel, M. J., Al-Batran, S. E., Kim, S.-Z., Welslau, M., Hecker, R., Kofahl-Krause, D., Josten, K.-M., Dürk, H., Rost, A., Neise, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.100 · Cited by 441
Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00010 · Cited by 434
Montoto, S., Davies, A. J., Matthews, J., Calaminici, M., Norton, A. J., Amess, J., Vinnicombe, S., Waters, R., Rohatiner, A. Z. S., & Lister, T. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3260 · Cited by 397
Ardeshna, K. M., Qian, W., Smith, P., Braganca, N., Lowry, L., Patrick, P., Warden, J., Stevens, L., Pocock, C. F. E., Miall, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70027-0 · Cited by 395
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Dreyling, M., Santoro, A., Mollica, L., Leppä, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4648 · Cited by 395
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial
Lowry, L., Smith, P., Qian, W., Falk, S., Benstead, K., Illidge, T., Linch, D., Robinson, M., Jack, A., & Hoskin, P. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.013 · Cited by 386
New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma
Fisher, R. I., LeBlanc, M., Press, O. W., Maloney, D. G., Unger, J. M., & Miller, T. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1674 · Cited by 375
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Morschhauser, F., Fowler, N. H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M. L., Fruchart, C., Libby, E. N., Casasnovas, R.-O., Flinn, I. W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805104 · Cited by 373
Robinson, K. S., Williams, M. E., van der Jagt, R. H., Cohen, P., Herst, J. A., Tulpule, A., Schwartzberg, L. S., Lemieux, B., & Cheson, B. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.0001 · Cited by 353
Link, B. K., Maurer, M. J., Nowakowski, G. S., Ansell, S. M., Macon, W. R., Syrbu, S. I., Slager, S. L., Thompson, C. A., Inwards, D. J., Johnston, P. B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3990 · Cited by 335
Flinn, I. W., van der Jagt, R., Kahl, B., Wood, P., Hawkins, T., MacDonald, D., Simpson, D., Kolibaba, K., Issa, S., Chang, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00605 · Cited by 311
Friedberg, J. W., Cohen, P., Chen, L., Robinson, K. S., Forero-Torres, A., La Casce, A. S., Fayad, L. E., Bessudo, A., Camacho, E. S., Williams, M. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5070 · Cited by 296
Hagenbeek, A., Gadeberg, O., Johnson, P., Møller Pedersen, L., Walewski, J., Hellmann, A., Link, B. K., Robak, T., Wojtukiewicz, M., Pfreundschuh, M., et al. (2008) · Blood · doi:10.1182/blood-2007-10-117671 · Cited by 264
Flinn, I. W., Miller, C. B., Ardeshna, K. M., Tetreault, S., Assouline, S. E., Mayer, J., Merli, M., Lunin, S. D., Pettitt, A. R., Nagy, Z., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00915 · Cited by 264
Self-citationLadetto, M., De Marco, F., Benedetti, F., Vitolo, U., Patti, C., Rambaldi, A., Pulsoni, A., Musso, M., Liberati, A. M., Olivieri, A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116749 · Cited by 253
Hoskin, P. J., Kirkwood, A. A., Popova, B., Smith, P., Robinson, M., Gallop-Evans, E., Coltart, S., Illidge, T., Madhavan, K., Brammer, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70036-1 · Cited by 247
Canioni, D., Salles, G., Mounier, N., Brousse, N., Keuppens, M., Morchhauser, F., Lamy, T., Sonet, A., Rousselet, M.-C., Foussard, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.8298 · Cited by 247
Schuster, S. J., Neelapu, S. S., Gause, B. L., Janik, J. E., Muggia, F. M., Gockerman, J. P., Winter, J. N., Flowers, C. R., Nikcevich, D. A., Sotomayor, E. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3005 · Cited by 245
Fisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D., Vose, J. M., Leonard, J. P., Kroll, S., Goldsmith, S. J., & Coleman, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.9217 · Cited by 240
Hiddemann, W., Barbui, A. M., Canales, M. A., Cannell, P. K., Collins, G. P., Dürig, J., Forstpointner, R., Herold, M., Hertzberg, M., Klanova, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8960 · Cited by 240
Sarkozy, C., Maurer, M. J., Link, B. K., Ghesquieres, H., Nicolas, E., Thompson, C. A., Traverse-Glehen, A., Feldman, A. L., Allmer, C., Slager, S. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00400 · Cited by 240
Schmatz, A.-I., Streubel, B., Kretschmer-Chott, E., Püspök, A., Jäger, U., Mannhalter, C., Tiemann, M., Ott, G., Fischbach, W., Herzog, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.9193 · Cited by 231
Glas, A. M. (2005) · Blood · doi:10.1182/blood-2004-06-2298 · Cited by 225
Lee, A. M., Clear, A. J., Calaminici, M., Davies, A. J., Jordan, S., MacDougall, F., Matthews, J., Norton, A. J., Gribben, J. G., Lister, T. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4642 · Cited by 220
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
Bachy, E., Maurer, M. J., Habermann, T. M., Gelas-Dore, B., Maucort-Boulch, D., Estell, J. A., Van den Neste, E., Bouabdallah, R., Gyan, E., Feldman, A. L., et al. (2018) · Blood · doi:10.1182/blood-2017-11-816405 · Cited by 211
Morschhauser, F., Radford, J., Van Hoof, A., Botto, B., Rohatiner, A. Z. S., Salles, G., Soubeyran, P., Tilly, H., Bischof-Delaloye, A., van Putten, W. L. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6400 · Cited by 206
Witzig, T. E., Vukov, A. M., Habermann, T. M., Geyer, S., Kurtin, P. J., Friedenberg, W. R., White, W. L., Chalchal, H. I., Flynn, P. J., Fitch, T. R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.052 · Cited by 200
Kahl, B. S., Hong, F., Williams, M. E., Gascoyne, R. D., Wagner, L. I., Krauss, J. C., Habermann, T. M., Swinnen, L. J., Schuster, S. J., Peterson, C. G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5853 · Cited by 195
Dupuis, J., Berriolo-Riedinger, A., Julian, A., Brice, P., Tychyj-Pinel, C., Tilly, H., Mounier, N., Gallamini, A., Feugier, P., Soubeyran, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0934 · Cited by 191
Transformation of Indolent B-Cell Lymphomas
Montoto, S., & Fitzgibbon, J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7577 · Cited by 190
Radioimmunotherapy of non-Hodgkin lymphomas
Cheson, B. D. (2003) · Blood · doi:10.1182/blood-2002-06-1793 · Cited by 180
Leonard, J. P., Jung, S.-H., Johnson, J., Pitcher, B. N., Bartlett, N. L., Blum, K. A., Czuczman, M., Giguere, J. K., & Cheson, B. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.9258 · Cited by 180
Witzig, T. E., Molina, A., Gordon, L. I., Emmanouilides, C., Schilder, R. J., Flinn, I. W., Darif, M., Macklis, R., Vo, K., & Wiseman, G. A. (2007) · Cancer · doi:10.1002/cncr.22617 · Cited by 176
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
Hirayama, A. V., Gauthier, J., Hay, K. A., Voutsinas, J. M., Wu, Q., Pender, B. S., Hawkins, R. M., Vakil, A., Steinmetz, R. N., Riddell, S. R., et al. (2019) · Blood · doi:10.1182/blood.2019000905 · Cited by 173
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Bartlett, N. L., Costello, B. A., LaPlant, B. R., Ansell, S. M., Kuruvilla, J. G., Reeder, C. B., Thye, L. S., Anderson, D. M., Krysiak, K., Ramirez, C. A., et al. (2017) · Blood · doi:10.1182/blood-2017-09-804641 · Cited by 165
Morschhauser, F., Leonard, J. P., Fayad, L., Coiffier, B., Petillon, M.-O., Coleman, M., Schuster, S. J., Dyer, M. J. S., Horne, H., Teoh, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9117 · Cited by 164
Guadagnolo, B. A., Li, S., Neuberg, D., Ng, A., Hua, L., Silver, B., Stevenson, M. A., & Mauch, P. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.08.010 · Cited by 159
Prognostic Factors in Follicular Lymphoma
Relander, T., Johnson, N. A., Farinha, P., Connors, J. M., Sehn, L. H., & Gascoyne, R. D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1693 · Cited by 159
Wahlin, B. E., Sander, B., Christensson, B., & Kimby, E. K. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1734 · Cited by 158
Louissaint, A., Schafernak, K. T., Geyer, J. T., Kovach, A. E., Ghandi, M., Gratzinger, D., Roth, C. G., Paxton, C. N., Kim, S., Namgyal, C., et al. (2016) · Blood · doi:10.1182/blood-2015-12-682591 · Cited by 158
Friedberg, J. W., Kim, H., McCauley, M., Hessel, E. M., Sims, P. W., Fisher, D. C., Nadler, L. M., Coffman, R. L., & Freedman, A. S. (2004) · Blood · doi:10.1182/blood-2004-06-2156 · Cited by 154
Self-citationChromatin modifying gene mutations in follicular lymphoma
Green, M. R. (2017) · Blood · doi:10.1182/blood-2017-08-737361 · Cited by 152
Schmidt, J., Gong, S., Marafioti, T., Mankel, B., González‐Farré, B., Balagué, O., Mozos, A., Cabeçadas, J., van der Walt, J. D., Hoehn, D., et al. (2016) · Blood · doi:10.1182/blood-2016-03-703819 · Cited by 144
Friedberg, J. W., Neuberg, D. S., Gribben, J. G., Fisher, D. C., Canning, C. M., Koval, M. A., Poor, C. M., Green, L. M., Daley, J. F., Soiffer, R. J., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03535.x · Cited by 140
Self-citationHans, C. P., Weisenburger, D. D., Vose, J. M., Hock, L. M., Lynch, J. C., Aoun, P. A., Greiner, T. C., Chan, W. C., Bociek, R. G., Bierman, P. J., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2298 · Cited by 140
Freedman, A. S., Neelapu, S. S., Nichols, C. R., Robertson, M. J., Djulbegović, B., Winter, J. N., Bender, J. F., Gold, D. P., Ghalie, R., Stewart, M. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8903 · Cited by 138
Self-citationJunlén, H. R., Peterson, S., Kimby, E. K., Lockmer, S., Lindén, O., Nilsson‐Ehle, H., Erlanson, M., Hagberg, H., Rådlund, A., Hagberg, O., et al. (2014) · Leukemia · doi:10.1038/leu.2014.251 · Cited by 135
Davies, A., Merli, F., Mihaljević, B., Mercadal, S., Siritanaratkul, N., Solal-Céligny, P., Boehnke, A., Berge, C., Genevray, M., Zharkov, A., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30078-9 · Cited by 125
Kiaii, S., Clear, A. J., Ramsay, A. G., Davies, D. C., Sangaralingam, A., Lee, A. R. I., Calaminici, M., Neuberg, D. S., & Gribben, J. G. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2137 · Cited by 112
Early lesions of follicular lymphoma: a genetic perspective
Mamessier, É., Song, J. Y., Eberle, F. C., Pack, S., Drevet, C., Chetaille, B., Abdullaev, Z., Adélaı̈de, J., Birnbaum, D., Chaffanet, M., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.094474 · Cited by 112
Kahl, B. S., Byrd, J. C., Flinn, I. W., et al. (2010) · Blood · doi:10.1182/blood.v116.21.1777.1777 · Cited by 109
Gopal, A. K., Schuster, S. J., Fowler, N. H., Trotman, J., Heß, G., Hou, J., Yacoub, A., Lill, M., Martin, P., Vitolo, U., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8853 · Cited by 105
Highly increased familial risks for specific lymphoma subtypes
Goldin, L. R., Björkholm, M., Kristinsson, S. Y., Turesson, I., & Landgren, O. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07721.x · Cited by 101
Nooka, A. K., Nabhan, C., Zhou, X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds429 · Cited by 98
Shadman, M., Li, H., Rimsza, L., Leonard, J. P., Kaminski, M. S., Braziel, R. M., Spier, C. M., Gopal, A. K., Maloney, D. G., Cheson, B. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5083 · Cited by 86
Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma
Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., Connors, J. M., Berinstein, N. L., Belch, A. R., Bartlett, N. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.9273 · Cited by 85
Self-citationAutologous Stem Cell Transplantation in Follicular Lymphoma: a Systematic Review and Meta-analysis
Khabori, M. A., de Almeida, J. R., Guyatt, G. H., Kuruvilla, J. G., & Crump, M. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr450 · Cited by 83
Martin, P., Jung, S., Pitcher, B. N., Bartlett, N. L., Blum, K. A., Shea, T., Hsi, E. D., Ruan, J., Smith, S. E., Leonard, J. P., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx496 · Cited by 83
Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
Chau, I., Jones, R. L., Cunningham, D., Wotherspoon, A. C., Maisey, N. R., Norman, A. R., Jain, P., Bishop, L., Horwich, A., & Catovsky, D. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601006 · Cited by 82
Friedberg, J. W., Kelly, J. L., Neuberg, D. S., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07773.x · Cited by 81
Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk
Sud, A., Chattopadhyay, S., Thomsen, H., Sundquist, K., Sundquist, J., Houlston, R. S., & Hemminki, K. (2019) · Blood · doi:10.1182/blood.2019001362 · Cited by 81
Smith, S. M., Godfrey, J. K., Ahn, K. W., Digilio, A., Ahmed, S., Agrawal, V., Bachanová, V., Bacher, U., Bashey, A., Bolaños‐Meade, J., et al. (2018) · Cancer · doi:10.1002/cncr.31374 · Cited by 79
Sureda, A. M., Zhang, M., Dreger, P., Carreras, J., Fenske, T. S., Finel, H., Schouten, H. C., Montoto, S., Robinson, S. P., Smith, S. M., et al. (2018) · Cancer · doi:10.1002/cncr.31264 · Cited by 72
Hellmuth, J. C., Louissaint, A., Szczepanowski, M., Haebe, S., Pastore, A., Alig, S., Staiger, A. M., Hartmann, S., Kridel, R., Ducar, M. D., et al. (2018) · Blood · doi:10.1182/blood-2018-03-837252 · Cited by 72
Zucca, E., Rondeau, S., Vanazzi, A., Østenstad, B., Mey, U., Rauch, D., Wahlin, B. E., Hitz, F., Hernberg, M., Johansson, A., et al. (2019) · Blood · doi:10.1182/blood-2018-10-879643 · Cited by 68
Qu, X., Li, H., Braziel, R. M., Passerini, V., Rimsza, L. M., Hsi, E. D., Leonard, J. P., Smith, S. M., Kridel, R., Press, O. W., et al. (2018) · Blood · doi:10.1182/blood-2018-07-865428 · Cited by 66
CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma
Advani, R. H., Volkmer, J.-P., & Chao, M. P. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1816156 · Cited by 21
Cited by
Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C. Y., Dietrich, S., et al. (2025) · Blood · doi:10.1182/blood.2024025454 · Cited by 94
Metadata
- Authors
- Freedman, A., & Jacobsen, E.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2019-12-22
- Volume
- 95
- Issue
- 3
- Pages
- 316-327
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2994477221
- Cited by
- 268
- References
- 92
- FWCI
- 17.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.